Neuland Laboratories Ltd.

NSE: NEULANDLAB  SECTOR: Pharmaceuticals & Drugs

1081.2
+76.5 (7.61%)

Price Summary

Today's High

₹ 1099.85

Today's Low

₹ 997.75

52 Week High

₹ 1202.9

52 Week Low

₹ 247.3

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.

Company Essentials

Market Cap

1387.16759868 Cr.

Enterprise Value

1601.06579868 Cr.

No. of Shares

1.2829889 Cr.

P/E

54.78

P/B

1.93

Face Value

₹ 10

Div. Yield

0.18%

Book Value (TTM)

₹  560.9493

CASH

45.6924 Cr.

DEBT

259.5906 Cr.

Promoter Holding

35.86%

EPS (TTM)

₹  19.7375

Sales Growth

14.3786830066756%

ROE

2.26971197779355 %

ROCE

7.83573428800242 %

Profit Growth

2.0820604611866 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1w1m3m6m1Yr3Yr5Yr

* Prices are based on daily market changes.

Valuation Chart 1w1m3m6m1Yr3Yr5Yr

* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

Sales Growth (in Cr.)

1 Year14.38%
3 Year9.63%
5 Year10.21%

Profit Growth (in Cr.)

1 Year-1.63%
3 Year-30.04%
5 Year0.12%

ROE%

1 Year2.27%
3 Year3.56%
5 Year9.7%

ROCE %

1 Year7.84%
3 Year5.27%
5 Year10.05%

Debt/Equity

0.368367077178109

Price to Cash Flow

24.49

Interest Cover Ratio

3.43358335573954

CFO/PAT (5 Yr. Avg.)

2.276298134404

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2019 35.86 4.35
Sep 2019 35.86 4.35
Jun 2019 35.9 4.34
Mar 2019 35.9 4.34
Dec 2018 36.04 4.32
* Figures given above are % of equity capital

 Strengths

  • The company has a good cash flow management; CFO/PAT stands at 2.276298134404.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 4.99657953678404.

 Limitations

  • The company has shown a poor profit growth of -30.0434562100188% for the Past 3 years.
  • The company has shown a poor revenue growth of 9.62823780961166% for the Past 3 years.
  • Company has a poor ROE of 3.56495439423863% over the past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020
Net Sales 181.01 186.22 203.62 191.87 205.42
Total Expenditure 162.44 161.38 175.56 161.87 171.69
Operating Profit 18.57 24.83 28.06 29.99 33.74
Other Income 0.52 0.57 1.02 1.78 0.7
Interest 4.03 4.78 5.69 7.07 5.37
Depreciation 7.55 8.28 7.82 7.63 8.86
Exceptional Items 0 0 0 0 0
Profit Before Tax 7.51 12.34 15.58 17.08 20.2
Tax 1.89 3.77 4.53 26.43 5.15
Profit After Tax 5.61 8.57 11.04 -9.35 15.06
Adjusted EPS (Rs) 0.44 0.66 0.86 -0.72 1.17

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 509.97 578.89 527.41 666.83 762.71
Total Expenditure 430.1 473.2 477.38 608.96 661.25
Operating Profit 79.87 105.69 50.03 57.87 101.46
Other Income 1.62 1.17 4.53 3.49 3.89
Interest 24.47 21.08 18.92 15.66 21.57
Depreciation 15.74 19.23 22.1 25.86 31.28
Exceptional Items 0 0 0 0 0
Profit Before Tax 41.28 66.55 13.54 19.84 52.5
Tax 14.87 20.17 1.73 3.69 36.62
Net Profit 26.41 46.38 11.81 16.14 15.88
Adjusted EPS (Rs.) 29.74 52.21 13.29 12.58 12.38

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 8.95 8.95 8.95 12.9 12.9
Total Reserves 175.22 533.82 545.83 682.68 692.64
Borrowings 45.4 29.81 103.49 60.72 77.37
Other N/C liabilities 23.61 24.02 42.29 42.41 84.83
Current liabilities 270.16 288.24 370.38 331.19 361.99
Total Liabilities 523.34 884.85 1070.94 1129.9 1229.74
Assets
Net Block 138.77 435.74 445.01 511.67 622.75
Capital WIP 40.48 19.6 126.09 104.47 23.75
Investments 7.55 30.36 30.37 30.37 30.33
Loans & Advances 22.71 24.69 22.52 30.45 35.78
Other N/C Assets 0.5 0.22 0.22 0 3.3
Current Assets 313.34 374.24 446.73 452.93 513.83
Total Assets 523.34 884.85 1070.94 1129.9 1229.74
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit Before Tax 41.28 66.55 13.54 19.84 52.5
Adjustment 33.85 43.95 40.35 38.93 58.14
Working Capital Changes -18.76 -55.25 -39.2 15.92 -49.3
Tax Paid -11.73 -16.36 -3.17 -5.09 -4.7
Operating Cash Flow 44.65 38.89 11.52 69.6 56.63
Investing Cash Flow -19.86 -42.11 -116.29 -77.22 -48.68
Financing Cash Flow -23.62 -0.08 104.86 11.98 -5.48
Net Cash Flow 1.18 -3.3 0.09 4.36 2.47

Corporate Actions

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.
Report us

Company News

Neuland Laboratories Stock Price Analysis and Quick Research Report. Is Neuland Laboratories an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Neuland Laboratories and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 56.6314 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Neuland Laboratories has a Debt to Equity ratio of 0.368367077178109 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Neuland Laboratories , the EPS growth was -1.63112834966612 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Neuland Laboratories has OPM of 13.3022634529366 % which is a bad sign for profitability.
     
  • ROE: Neuland Laboratories have a poor ROE of 2.26971197779355 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Neuland Laboratories

X